

Company Information and Initial Disclosure Statement

Protext Mobility, Inc.
OTCPK: TXTM

Part A General Company Information

Item I - The exact name of the issuer.

Protext Mobility, Inc. (hereinafter referred to as “we”, “us”, or “our” or “issuer”).
Name used by predecessor entities in the past 5 years: none

Item II - The address of the issuer’s principal executive offices.

2255 Glades Road, #324A and #319A
Boca Raton, Florida
Phone: (435)881-3611
Email: info@Protex-tm.co
Website: www.Protex-tm.co

IR Contact: David Lewis
(617)504-3636
info@Protex-tm.co

Item III - Jurisdiction and date of the incorporation.

The Company was incorporated on September 5, 2001 in the state of Delaware.

Part B Share Structure

Item IV - The exact title and class of securities outstanding.

Common Stock - Cusip # 74371E204
Trading symbol: TXTM

Preferred Stock – We have four classes of preferred stock, designated Series A through D

Item V - Par or stated value and description of the security.

Common Stock
Par value \$0.00001

Registered Under Exchange Act: Yes
Regulatory Authority: Securities & Exchange Commission (SEC)

List any restrictions on the transfer of security: None

Describe any trading suspension orders issued by the SEC in the past 12 months: None

Our common shares have no associated dividend or pre-emptive rights. Common shares have one vote per share on all shareholder matters. There are no other material rights of the common stockholders. There are no provisions in our charter or bylaws that would delay or prevent a change in control.

Preferred Stock

Series A – Par value \$0.001, 100,000 shares authorized.

As a class, the Series A Preferred can convert into that number of common shares equal to 20% of the post-conversion issued and outstanding shares of common stock. Individual shares of Series A Preferred may convert into that pro-rata number of common shares equal to 1/100,000 of the total shares issuable to the entire class. The Series A Preferred has rights voting rights equal to that number of common shares into which the class is convertible on all shareholder matters. The Series A Preferred has no associated dividend or pre-emptive rights. There are no other material rights of the Series A Preferred stockholders.

Series B – Par value \$0.0001, 1,000,000 shares authorized.

Each share of Series B Preferred has voting rights equal to two votes on all shareholder matters. The Series B Preferred Stock converts to common stock on a 100:1. There are no other material rights of the Series B Preferred stockholders.

Series C – Par value \$0.001, 10,000,000 shares authorized.

Each share of Series C Preferred has voting rights equal to 200 votes on all shareholder matters. The Series C Preferred has no associated dividend or pre-emptive rights. There are no other material rights of the Series C Preferred stockholders.

Series D – Par value \$0.001, 100,000 shares authorized.

As a class, the Series D Preferred can convert into that number of common shares equal to 75% of the post-conversion issued and outstanding shares of common stock. Individual shares of Series D Preferred may convert into that pro-rata number of common shares equal to 1/100,000 of the total shares issuable to the entire class. The Series D Preferred has rights voting rights equal to that number of common shares into which the class is convertible on all shareholder matters. The Series D Preferred has no associated dividend or pre-emptive rights. There are no other material rights of the Series D Preferred stockholders.

Item VI - The number of shares or total amount of the securities outstanding for each class of securities authorized.

In answering this item, provide the information below for each class of securities authorized. Please provide this information (i) as of the end of the issuer's most recent fiscal quarter and (ii) as of the end of the issuer's last two fiscal years.

Date	Class or Series	# Shares Authorized	# Shares Outstanding	Shares in the Float	Beneficial Shareholders	Shareholders of Record
12/31/2016	Common	10,000,000,000	1,946,690,324	1,716,220,028	-	36
	Series A	100,000	79,450	-	-	3
	Series B	1,000,000	504,003	-	-	1
	Series C	10,000,000	2,675,000	-	-	1
	Series D	100,000	100,000	-	-	1
12/31/2015	Common	10,000,000,000	1,724,690,324	1,716,220,028		36
	Series A	100,000	-	-	-	-
	Series B	1,000,000	550,055	-	-	4

	Series C	10,000,000	9,000,000	-	-	2
	Series D	100,000	-	-	-	-

Part C Business Information

Item VII- Name and Address of Transfer Agent

Transfer Agent:

ClearTrust, LLC

16540 Pointe Village Dr, Ste 210

Lutz, FL 33558

Phone: 813.235.4490

www.ClearTrustOnline.com

Our transfer agent is registered under the Exchange Act, and is regulated by the Securities and Exchange Commission.

Item: VIII - Nature of the business

Protext Mobility Inc. was incorporated in the State of Delaware on September 5, 2001 under the name SearchHelp, Inc. and completed its initial public offering on July 23, 2003. During the fiscal year ended December 31, 2008, the Company acquired 100% of the stock of EchoMetrix, Inc, which then became a wholly owned subsidiary, and in May of 2009 the Company filed a Certificate of Ownership and Merger with the State of Delaware pursuant to which EchoMetrix was merged with and into the Company, and the Company's corporate name was changed to EchoMetrix, Inc. In December 2010, filed a Certificate of Ownership and Merger with the state of Delaware pursuant to which the Company's then wholly owned subsidiary, Protext Mobility, Inc., was merged with and into the Company, and the Company's corporate name was changed to Protext Mobility, Inc.

On December 31, 2016, the Company acquired Plandaí Biotechnology South Africa (Pty) Ltd. (Plandaí), a South African company headquartered in the Mpumalanga province of South Africa through a share exchange agreement. Under the terms of acquisition, the Company issued 100,000 shares of Series D Preferred Stock in exchange for all of the issued and outstanding shares of Plandaí. The Series D Preferred have the right to convert into 75% of the post-conversion issued and outstanding common stock of the Company. The Series D Preferred have voting rights equal to the number of shares issuable on conversion on all shareholder matters.

As a result of the transaction with Plandaí, the shareholders of Plandaí became the control entity, having voting and conversion rights equal to 75%. While Plandaí is a legal subsidiary of the Company, Plandaí elected to become the successor issuer to the Company for accounting and reporting purposes.

The Company at no time in its history has been a shell. There has never been a filing in bankruptcy, receivership The issuer is not now nor has it ever been a shell company. There is no pending or threatened legal action. There have not been any defaults on any notes, leases or other obligations. The company's stock has never been delisted by any securities exchange or by the OTC Bulletin Board. Since inception, there has been no forward splits of the company's stock, stock dividend, recapitalization, reorganization, or spin off. On February 5th, 2014, the Company completed a 1 for 800 reverse stock split. The company has been in continuous operations since inception.

Business Description:

The issuer's primary and secondary SIC codes:

Primary Code: 2833
Secondary Code: 2834

Following the Share Exchange Agreement completed December 31, 2016, the Company's operations became those of Plandaí Biotechnology South Africa (Pty) Ltd. Plandaí was formed in 2014 and focuses on the development of pharmaceutical applications for botanical drugs and has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients.

Item IX - The nature of products or services offered

Products

The Company focuses on the development of pharmaceutical applications for botanical drugs and has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients.

Marketing

Following successful clinical trials, the Company will produce a finished product, expected to consist of a gel-cap or twin-capsule containing Phytofare® and/or Phytofare® mixed with other ingredients. We anticipate that these capsules will be marketed through various distributors to retail manufacturers for private label products.

The benefit of conducting human clinical trials is that, if successful, the Company can then apply for "claims" from the FDA and other international oversight agencies respecting the use of our products for treating one or more conditions or diseases. The types of claims that can be sought and awarded vary country-by-country; however, the awarding of claims enables the Company to market the product for specific applications rather than simply for "general wellness." This creates a significant competitive advantage over generic extracts and other branded ingredients. Our marketing efforts will, to a large degree, be dictated by the nature of claims awarded and will be largely country-specific.

In addition to the use of distributors, we may employ direct sales representatives in certain areas, participate in trade shows, and purchase media spots where appropriate. Direct-to-consumer sales are not part of the initial marketing strategy owing to the high cost associated with marketing a single product to consumers and buying and stocking retail space.

Item X - Facilities.

The Company presently leases executive offices at 2255 Glades Road, Suites 324A and 319A, Boca Raton, Florida under a 12-month contract. We also lease approximately 2,500 square feet of business

space located at 9 Palm Street, White River 1240, Mpumalanga, South Africa, which houses administrative and executive management personnel. This space is leased under a five-year term with an option to purchase. Management believes that these facilities are adequate for operations for the coming twelve months.

Part D Management and Control Structure

Item XI - The name of the chief executive officer, members of the board of directors, as well as control persons

A. Officers and Directors

Roger Baylis-Duffield
Chief Executive Officer and Director
Compensation: \$90,000 per year
Person Named above does not own any shares of the Company.

David Lewis
Director
Compensation: N/A
Person named above owns 49,500 shares of Series A Preferred stock.

B. Legal/Disciplinary History.

None of our officers or directors have been the subject of a conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; a finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; the entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Disclosure of Family Relationships.

There are no family relationships among and between our directors, officers or beneficial owners of more than five percent (5%) of the any class of our equity securities.

D. Disclosure of Related Party Transactions.

There are no related party transactions.

E. Disclosure of Conflicts of Interest.

We are unaware of any conflicts of interest with any of our officers, directors or owners of more than five percent of our equity securities.

Item XII - Financial information for the issuer's most recent fiscal period.

Financial Statements incorporated by reference (published separately):

Annual Report 12/31/2016 posted to otcq.com on _____

Annual Report 12/31/2015 posted to otcq.com on _____

Item XIV - Beneficial Owners.

Plandaí Biotechnology, Inc. ⁽¹⁾ 17 Hanover Square London, England			
	Series D Preferred	100,000	100%
Steve Berman ⁽²⁾	Series C Preferred	2,675,000	100%
Jay Safier ⁽²⁾	Series B Preferred	46,052	100%
Rock Island Capital ⁽²⁾	Series A Preferred	10,000	10%
Richard Grossfeld ⁽²⁾	Series A Preferred	19,950	19.95%
David Lewis ⁽²⁾	Series A Preferred	49,500	49.50%

⁽¹⁾ Plandaí Biotechnology, Inc., is majority controlled by Moor Holdings, a private trust of which Roger Baylis-Duffield and his wife are the primary beneficiaries. Mr. Baylis-Duffield is the Chairman and Chief Executive Officer of Plandaí Biotechnology, a Nevada Corporation. His address is 9 Palm Street, White River 1240, Mpumalanda, South Africa.

⁽²⁾ The address for these listed individuals is 2255 Glades Road, Suite 324A, Boca Raton, Florida.

Item XV - The name address, telephone number, and email address of each of the following outside providers.

- | | |
|---------------------------|---|
| 1. Investment Banker: | None |
| 2. Promoters: | None |
| 3. Counsel: | Mailander Law Office, Inc.
835 5 th Avenue, Suite 312
San Diego, CA 92101
(619)239-9034 |
| 4. Accountant or Auditor: | HE Merrill Advisory
1651 North 400 East, #614
North Logan, UT 84341
(435)881-3611 |

5. Investor Relations Consultant: None
6. Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement: None

Item XVI. – Management’s Discussion and Analysis or Plan of Operation.

A. Plan of Operation

Over the coming fiscal year, the company will employ an aggressive strategy for implementing its business plan. The initial focus will be on completing a clinical trial to determine the effectiveness of controlling blood sugar and glucose levels in diabetic and pre-diabetic individuals. This trial is expected to commence in the first half of 2017 and conclude before the end of the year.

Should the clinical trial prove successful, the Company will file for the right to claim medical benefit in its marketing and promotional materials. These claims, such as a structure function claim, would allow companies selling our products to consumers to advertise, promote and claim on the packaging that consuming Phytofare® has a specific, proven medicinal benefit to consumers.

As various claims are approved by the different regulatory bodies, the Company will commence selling and marketing its products throughout the world under the approved claims. The initial strategy will be to sell a pre-formulated capsule to various finished product manufacturers for their private label applications. We anticipate entering the market with product by the end of calendar 2017 or the first quarter of 2018.

The Company is able to source its raw materials (Phytofare®) from its majority shareholder, Plandaí Biotechnology, Inc. (“Plandaí”). Plandaí controls an 8,000-acre tea estate in Mpumalanga, South Africa, and a 100,000ft² manufacturing facility located on-site. We have a minimum guarantee supply agreement as well as secured a worldwide exclusive license from Plandaí to develop and sell Phytofare® extracts for pharmaceutical applications and have supply agreements in place to ensure quantity and price needs are met.

B. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company did not generate any revenues during the years ended December 31, 2016 or 2015 and no significant revenues are expected for 2017. Following the initial product launch, we anticipate sales commencing late in 2017.

Operating Expenses for all periods presented consisted primarily of salary and wages for our President and lead researcher, Mr. Baylis-Duffield of \$90,000 per year, and consulting expenses of \$60,000 per year. In addition, the company incurred rent expense of \$1,700 per month (\$20,400 annually) associated with office and laboratory space in Mpumalanga, South Africa. We anticipate expenses increasing significantly in 2017 as we commence clinical trials, including research costs, travel, and administrative costs.

C. Off-Balance Sheet Arrangements.

We do not have any off-balance sheet arrangements.

Part E – Issuance History

Item XVII - List of securities offerings and shares issued for services in the past two years.

List below any events in chronological order that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities.

During 2015, the Company issued 344,917,800 restricted common shares upon conversion of convertible notes and associated interest of \$16,545.89

During 2016 the Company issued 222,000,000 restricted common shares to settle certain of the Company's convertible debt and associated interest of \$8,595.

On December 31, 2016, the Company issued 79,450 shares of Series A Preferred on the exchange of 504,003 shares of Series B Preferred. Simultaneously, we issued 100,000 shares of Series D Preferred in exchange for all of the outstanding capital of Plandaí Biotechnology South Africa (Pty) Ltd.

Part F – Exhibits

Item XVIII - Material Contracts.

License Agreement with Plandaí Biotechnology, Inc.

Item XIX - Articles of Incorporation and Bylaws

The Company's Articles of Incorporation and Bylaws, as amended, are filed herewith.

Item XX - Purchase of Equity Securities by the Issuer and Affiliated Purchasers

There has been no purchase of Equity Securities by the Issuer or Affiliates

Item XXI - Issuer Certification

I, Roger Baylis-Duffield, certify that:

1. I have reviewed this initial disclosure statement of Protext Mobility, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: /s/ Roger Baylis-Duffield

Roger Baylis-Duffield

/S/ Roger Baylis-Duffield

Chief Executive Officer